Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046218 | 0.84 | POLB (0.47) | HCRTR2SERPINE1POLBMEN1KMT2A | |
| SCHEMBL9819029 | 0.83 | GPBAR1 (0.42) | HCRTR2SERPINE1POLBMLYCDEPHX2 | |
| SCHEMBL24794526 | 0.82 | HCRTR2 (0.46) | HCRTR2SERPINE1POLBMLYCDTSHR | |
| SCHEMBL11647636 | 0.76 | TSHR (0.59) | TSHRMEN1KMT2AHTT | |
| SCHEMBL4145118 | 0.75 | SERPINE1 (0.45) | HCRTR2SERPINE1POLBTSHREPHX2 | |
| SCHEMBL6575822 | 0.75 | SERPINE1 (0.45) | HCRTR2SERPINE1POLBTSHREPHX2 | |
| SCHEMBL136576 | 0.72 | MMP2 (0.47) | TSHREPHX2MEN1KMT2AHDAC3 | |
| SCHEMBL30677743 | 0.71 | EPHX2 (0.52) | HCRTR2SERPINE1MLYCDEPHX2 | |
| SCHEMBL21649311 | 0.71 | POLB (0.48) | HCRTR2SERPINE1POLBMLYCDTSHR | |
| SCHEMBL1147510 | 0.69 | MMP3 (0.42) | HCRTR2SERPINE1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | HCRTR2 1414/4885SERPINE1 4049/4885POLB 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.